Stay informed with the latest litigation news. Explore now

IP Verse

Idorsia Pharmaceuticals competitive analysis

Latest publications and patents of Idorsia Pharmaceuticals New

Explore the latest publications and patents granted to Idorsia Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Sep 8, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Idorsia Pharmaceuticals

EP4014976
Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)Granted And Under Opposition
EP3044211
Jan 3, 2018Antibacterial 2H-Indazole DerivativesNo Opposition Filed Within Time Limit

Latest patents of Idorsia Pharmaceuticals opposed by its competitors

Explore Idorsia Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4014976
Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)1

Latest PTAB cases involving Idorsia Pharmaceuticals New

Discover the latest PTAB cases involving Idorsia Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Top competitors of Idorsia Pharmaceuticals

Top competitors of Idorsia Pharmaceuticals based on patent oppositions.